In a rare move, the Trump Administration has taken steps to possibly invoke march-in rights on patents held by Harvard University, citing unmet obligations related to federally funded research. The action, as reported on August 8, 2025, by Law360, could see the government take control of intellectual property developed with federal assistance.
March-in rights, a feature of the Bayh-Dole Act, allow the government to intervene and take ownership of patents if the original holder fails to commercialize the technology to a degree that meets public needs, or if they cannot meet requirements set under federal funding agreements. Allegations that Harvard has not fulfilled these responsibilities could allow the Department of Commerce to enforce these rights.
The implications of this move could resonate throughout the research community, especially among institutions heavily reliant on federal research funding. Harvard, recognized globally for its research contributions, stands to lose control of significant biotechnology innovations if these rights are successfully invoked.
While the current political landscape adds a layer of complexity, this situation could set a precedent affecting university-industry partnerships and the handling of innovations derived from public funding. The circumstances leading to this conflict, according to reports by IP Watchdog, stem from broader concerns about equitable access to resulting products and technologies.
This situation underscores the ongoing tension between public interests and private patent rights, raising questions about how federally funded research results should be managed to best serve public welfare. Legal experts and university leaders are closely monitoring developments, aware that the outcome could influence future policymaking and the traditional autonomy universities have enjoyed over their innovations.